| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
49 companies · Health Care
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Nov 7, 2025 | BLLN Billiontoone, INC. | Tsao David | Chief Technology Officer | Buy | 1,000 | $60.00 | $60,000.00 | New | |
| Nov 7, 2025 | CDNA Caredx, INC. | Novack Jeffrey Adam | Secretary And General Counsel | Sell | 2,688 | $15.52 | $41,722.87 | -2.5% | |
| Nov 7, 2025 | BLLN Billiontoone, INC. | Johnson Nancy Joann | See Remarks | Buy | 6,900 | $60.00 | $414,000.00 | +23.8% | |
| Nov 7, 2025 | BLLN Billiontoone, INC. | Ten Bosch John Roderick | See Remarks | Buy | 800 | $60.00 | $48,000.00 | +2.2% | |
| Nov 7, 2025 | BLLN Billiontoone, INC. | Bremner Thomas S | Director | Buy | 41,666 | $60.00 | $2,499,960.00 | +2.5% | |
| Nov 6, 2025 | BIO Bio-rad Laboratories, INC. | Barry James | EVP, President, Lsg | Sell | 700 | $306.18 | $214,288.51 | -57.9% | |
| Nov 5, 2025 | VCYT Veracyte, INC. | Jones Evan/ Fa | Director | Sell | 43,196 | $45.06 | $1,946,287.73 | -11.8% | |
| Nov 5, 2025 | VCYT Veracyte, INC. | Chambers Rebecca | Chief Financial Officer | Sell | 7,000 | $41.00 | $287,000.00 | -5.3% | |
| Nov 5, 2025 | VCYT Veracyte, INC. | McGuire Annie | SVP, General Counsel | Sell | 6,466 | $40.00 | $258,640.00 | -7.2% | |
| Nov 5, 2025 | VCYT Veracyte, INC. | Eastham Karin | Director | Sell | 9,674 | $40.02 | $387,191.21 | -41.6% | |
| Nov 5, 2025 | MEDP Medpace Holdings, INC. | Geiger Jesse J | President | Sell | 21,503 | $595.66 | $12,808,476.98 | -58.9% | |
| Nov 5, 2025 | CSTL Castle Biosciences INC | Maetzold Derek J | Pres. &Chief Exec. Officer | Sell | 2,915 | $31.79 | $92,671.71 | -2.6% | |
| Nov 4, 2025 | EXAS Exact Sciences CORP | Herriott James | SVP, General Counsel &Sec | Sell | 1,500 | $70.08 | $105,120.00 | -10.6% | |
| Nov 4, 2025 | EXAS Exact Sciences CORP | Baranick Brian | EVP, Gm, Precision Oncology | Sell | 2,858 | $70.08 | $200,288.64 | -11.3% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.